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Abstract 
We previously identified osteopontin (OPN) as a promising marker for the early 
detection of hepatocellular carcinoma (HCC). In this study, we investigated the 
association between pre-diagnostic circulating OPN levels and HCC incidence in a large 
population-based cohort. A nested-case control study was conducted within the EPIC 
cohort. During a mean follow-up of 4.8 years, 100 HCC cases were identified. Each 
case was matched to two controls and OPN levels were measured in baseline plasma 
samples. Viral hepatitis, liver function and alpha-fetoprotein (AFP) tests were also 
conducted. Conditional logistic regression models were used to calculate multivariable 
odds ratio (OR) and 95% confidence intervals (95%CI) for OPN levels in relation to 
HCC. Receiver operating characteristics curves were constructed to determine the 
discriminatory accuracy of OPN alone or in combination with other liver biomarkers in 
the prediction of HCC. OPN levels were positively associated with HCC risk (per 10% 
increment, ORmultivariable=1.30; 95%CI:1.14-1.48). The association was stronger among 
cases diagnosed within two years of follow-up. Adding liver function tests to OPN 
improved the discriminatory performance for subjects who developed HCC 
(AUC=0.86). For cases diagnosed within two years, the combination of OPN and AFP 
was best able to predict HCC risk (AUC=0.88). The best predictive model for HCC in 
this low-risk population is OPN in combination with liver function tests. Within two 
years of diagnosis, the combination of OPN and AFP best predicted HCC development, 
suggesting that measuring OPN and AFP could identify high-risk groups independently 
of a liver disease diagnosis.  
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Introduction 
Liver cancer is the sixth most commonly diagnosed cancer and the second leading cause 
of cancer death worldwide (1). Hepatocellular carcinoma (HCC), the most common 
type of liver cancer (2), is primarily associated with chronic hepatitis B and C virus 
(HBV/HCV) infections, heavy alcohol drinking, smoking, non-alcoholic steatohepatitis 
(NASH) and, in high incidence areas, dietary exposure to aflatoxin (3-5). HCC 
incidence rates have increased over the past 20 years in Western Europe and the United 
States (2). The aging HCV infected population and the growing pandemic of diabetes 
and obesity causing NASH are thought to be largely responsible for the observed surge 
in HCC incidence.  HCC is often diagnosed at a late stage and has poor prognosis due to 
limited treatment options. Because mainly small tumors are accessible to curative 
treatments and such tumors are asymptomatic, identification of high risk individuals 
that would benefit from surveillance and novel biomarkers for early detection of this 
highly lethal disease are urgently needed. For the last 40 years, α-fetoprotein (AFP) has 
been the only serum marker routinely used by clinicians together with ultrasound for the 
detection and surveillance of HCC, despite its low sensitivity (ranging from 41 to 65%) 
for the detection of early-stage HCC (6, 7). 
We have previously identified osteopontin (OPN) as an early stage HCC 
biomarker with greater performance than AFP as well as complementary properties to 
AFP in discriminating HCC patients in a population already at high risk for HCC 
development (8, 9). Furthermore, we showed that the performance of OPN remained 
intact a year prior to HCC diagnosis in this high risk group (8, 9). The performance of 
OPN for the early detection of HCC was further validated in independent studies (10-
12). OPN is an extracellular matrix protein that has been implicated in several 
carcinogenic and angiogenic processes, such as cell invasion, inflammation, tumor 
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progression, and metastasis (13, 14). High OPN levels have also been associated with 
reduced survival in patients with lung, prostate, breast or liver cancers (15, 16). 
The aim of this study was to investigate the behaviour of circulating OPN in 
periods preceding HCC diagnosis in the general population, taking advantage of the 
European Prospective Investigation into Cancer and Nutrition (EPIC) cohort, a large 
heterogeneous cohort of Europeans, with a nested case-control subset for which 
measurements of HBV/HCV infection status and liver function biomarkers were 
conducted. EPIC is a large prospective cohort of >520,000 participants from 10 Western 
European countries, designed to investigate the association between diet, lifestyle and 
environmental factors and the incidence of cancers and other chronic diseases (17, 18). 
In EPIC, it was reported that smoking contributed to more HCCs (47.6%) than chronic 
HBV (13.2%) and HCV (20.9%) infections. Heavy alcohol consumption (10.2%) and 
obesity (16.1%) also contributed to sizeable fractions of this disease burden. Over one-
third of HCCs could not be accounted for by exposure to at least one of the documented 
risk factors (19). In follow-up studies, associations with diet and vitamin D levels were 
reported (20, 21). The present study is the first to evaluate a novel biomarker for early 
detection of HCC and its behaviour in relation to time to diagnosis in EPIC. 
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Materials and methods 
Study Population and Follow-up for Cancer Incidence 
Detailed information on the study design, rationale and methods of the EPIC 
study, including assessment of diet and lifestyle factors, has been described previously 
(17, 18). Briefly, between 1991 and 2000 more than 520,000 men and women aged 20-
85 years were recruited in 23 centres throughout 10 European countries (Denmark, 
France, Germany, Greece, Italy, the Netherlands, Norway, Spain, Sweden, and the 
United Kingdom). At recruitment, standardised dietary, lifestyle and socio-demographic 
questionnaires including information on physical activity, education, smoking, medical 
history and anthropometric data were collected. Blood samples were collected from 
participants at recruitment, immediately processed and fractionated into plasma, serum, 
white blood cells and red blood cells. These bio-samples are stored under liquid N2 at 
the International Agency for Research on Cancer (IARC, Lyon, France) for all countries 
except Denmark and Sweden. All cohort members provided written informed consent. 
Ethical approval for this study was obtained from the IARC ethical review board (Lyon, 
France) and participating centres.  
Vital status follow-up (98.5% complete) is collected by record linkage with 
regional and/or national mortality registries in all countries except Germany and Greece, 
where follow-up is based on active follow-up through study subjects or their next-of-kin. 
Cancer incidence is determined through record linkage with population-based regional 
cancer registries (Denmark, Italy, the Netherlands, Norway, Spain, Sweden, and the 
United Kingdom) or via a combination of methods, including the use of health 
insurance records, contacts with cancer and pathology registries, and active follow-up 
through study subjects and their next-of-kin (France, Germany, Greece). For HCC, our 
definition is based on site C22.0 (with morphology codes 8170/3, 8171/3 and 8180/3). 
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For our study, the bases of diagnosis for definition of HCC cases were as follows: 
Clinical observation/investigation (n=5), laboratory/biochemical examination (n=12), 
radiological examination, computerized tomography scan, magnetic resonance scan 
(n=10), cytology/hematology, histology of primary tumor (n=71) and autopsy report 
(n=2). For this study, the latest date of complete information for cancer incidence and 
vital status ranged from December 2002 to December 2006. 
 
Ascertainment of HCC and Nested Case-control Study Design 
HCC was the primary outcome of interest in this study. HCC was defined as first 
incident tumor in the liver (C22.0 as per the 10th Revision of the International Statistical 
Classification of Diseases, Injury and Causes of Death [ICD-10]). For each identified 
case, the histology and the methods used to diagnose the cancer were reviewed to 
exclude metastatic cases or other types of liver cancers.  
The design of the nested case-control study has been previously described (19). 
A total of 125 HCC cases with available blood samples at baseline were identified 
between participants’ recruitment and 2006. For each case, two controls were selected 
by incidence density sampling from all cohort members alive and free of cancer (except 
non-melanoma skin cancer). The controls were matched by age at blood collection (±1 
year), sex, study center, date (±2 months) and time of the day (±3 hours) at blood 
collection, and by fasting status (<3/3-6/>6 hours) at blood collection. Women were 
additionally matched by menopausal status (pre-/peri-/postmenopausal) and hormone 
replacement therapy use at time of blood collection (yes/no). Participants with 
insufficient blood sample were excluded (Ncases = 25 and Ncontrols = 56). For six cases, 
only one eligible matched control was available. Therefore, the final sample size for the 
present analysis included 100 HCC cases and 194 controls. The number of HCC cases 
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per recruitment center is Denmark (N = 24), Germany (N = 20), Greece (N = 9), Italy 
(N = 14), Spain (N = 4), Sweden (N = 19), the Netherlands (N = 3), United Kingdom (N 
= 7).  
 
Serum Biomarkers 
Data for HBV and HCV seropositivity, for AFP and C-reactive protein (CRP) 
levels and for liver function tests, alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), gamma-glutamyltransferase (GGT), alkaline phosphatase 
(ALP), albumin and total bilirubin were available and measured as previously described 
(20). In addition, the ratio of AST/ALT and BARD score were calculated and used as 
markers of liver fibrosis (22). BARD score, a non-invasive scoring system used to 
predict fibrosis severity in patients with non-alcoholic fatty liver disease, was calculated 
as the sum of BMI >28 = 1 point, AST/ALT >0.8 = 2 points and diabetes = 1 point.  
Plasma concentrations of OPN were measured using a commercial ELISA kit from 
R&D Systems (Minneapolis, MN) as previously described (8). Briefly, 50 µl of diluted 
(1:100) plasma samples were added to the ELISA plates pre-coated with a capture OPN 
antibody. 
  
Statistical Analysis 
Relevant baseline lifestyle and socio-demographic characteristics were described 
among cancer cases and matched controls. To assess correlations between OPN and 
liver function tests and other relevant variables, spearman partial correlation coefficients 
adjusted for age at recruitment and sex were estimated in cases and controls. 
Conditional logistic regression models were used to estimate odds ratios (OR) and 95% 
confidence intervals (CI) for associations between OPN levels and HCC risk. OPN was 
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analyzed as continuous and categorical variables based on tertiles of the distribution 
among controls. Tests for linear trend were performed by assigning the median values 
of each tertile of OPN. For continuous analyses, OPN was log transformed for 
normalization and a unit of 10% increase in circulating OPN levels was used as the 
exposure variable in linear models. 
For all analyses, both crude and multivariable models were run. Crude models 
were conditioned on the matching factors while multivariable models were additionally 
adjusted for the following relevant confounding factors: baseline alcohol intake at 
recruitment (g/d), pattern of lifetime alcohol intake (never drinker, former light drinker, 
former heavy drinker, light drinker, never heavy drinker, periodically heavy drinker, 
always heavy drinker, unknown), body mass index (BMI; kg/m2), and smoking status 
(never, former, current, and not specified). Other factors (height, weight, waist 
circumference, waist-to-hip ratio, education, physical activity, self-reported diabetes, 
and dietary intake of energy, fiber, tea, coffee, red and processed meats, fish, fruits and 
vegetables) were tested as potential confounders, but were excluded from final models 
for parsimony, as they did not affect the observed risk estimates (change-in-estimate 
<10%). 
Potential effect modifications of the association between OPN levels and HCC 
risk by sex, age at recruitment, years of follow-up, baseline and lifetime alcohol 
consumption, and smoking status were evaluated in separate analyses by including 
interaction terms formed by the product of modifying variable categories and the values 
of OPN. The statistical models were adjusted for alcohol using a combination variable 
of alcohol intake at baseline (i.e. recruitment into the cohort) and alcohol drinking 
throughout life periods (at 20, 30, 40, 50 years of age). These data were derived from 
standardized/validated dietary and lifestyle questionnaires (17). Participants classified 
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as never drinkers indicated no alcohol intake at baseline, and no past alcohol intake. 
Former drinkers indicated no alcohol intake at baseline, but did have past alcohol 
intake. Drinkers at recruitment indicated alcohol intake at baseline, but did not have past 
alcohol intake. Lifetime drinkers were defined as those who indicated alcohol intake at 
both baseline and prior. All the categories of alcohol exposures assessed are mutually 
exclusive. 
Statistical significance of interactions (p<0.05) was assessed using likelihood 
ratio tests based on the models with and without the interaction terms. Sensitivity 
analyses were performed including additional adjustment and/or stratification by 
hepatitis status, AFP, BARD score, liver function tests, sex, years of follow-up and 
diabetes.  
P-values<0.05 were considered statistically significant. Analyses were 
performed using Stata version 11 (StataCorp, College Station, Texas) and R software, 
version 3.0.2 (R Foundation for Statistical Computing, Vienna, Austria). 
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Results 
Participants Characteristics and Baseline Circulating Osteopontin Levels.      
Baseline characteristics of the study participants (Ncases = 100 and Ncontrols = 194) and p 
values for differences are presented in Table 1. HCC cases were diagnosed on average 
4.8 (±2.9) years after recruitment and baseline blood collection. They were more likely 
to be men, and compared with controls, they were more likely to be current smokers, to 
have higher BMI and to have diabetes. They were also more likely to present at 
recruitment with higher alcohol intake and with chronic HBV or HCV infection. 
Baseline AFP levels and markers of liver function are also presented in Table 1. 
Compared to controls, HCC cases had higher levels of AFP (6.4 vs. 3.9 ng/ml), CRP (2 
vs. 1 mg/l) and liver enzymes (ALT: 33 vs. 7 U/l; AST: 44.5 vs. 19 U/l; GGT: 87 vs. 
22.5 U/l; ALP: 85 vs. 59 U/l). No difference in the ratio AST/ALT was observed. 
Overall, 42.0% of HCC cases had BARD scores of 3 or 4, predictive of severe fibrosis, 
compared to 25.3% in controls.  
OPN levels at baseline were significantly higher in HCC cases than in controls 
(67.4 vs. 53.7 ng/ml, p<0.0001) (Table 1 and Supplementary Figure S1). Spearman 
correlations between OPN levels and AFP, CRP or liver function tests among HCC 
cases and controls were calculated (Supplementary Table S1). Among controls, a 
significant negative correlation was observed between OPN and ALT (R=-0.21; 
p=0.004) or albumin (R=-0.37; p<0.0001). Among HCC cases, a positive correlation 
was observed between OPN and AFP (R=0.24; p=0.022), CRP (R=0.38; p<0.0001), 
AST (R=0.21; p =0.039), GGT (R=0.25; p=0.014) and ALP (R=0.36; p <0.0001) and a 
negative correlation was observed between OPN and albumin (R=-0.48; p<0.0001). 
 
Association Between Circulating OPN Levels and HCC risk 
Cancer Research. 
on July 14, 2016. © 2016 American Association forcancerpreventionresearch.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 23, 2016; DOI: 10.1158/1940-6207.CAPR-15-0434 
17 
 
A statistically significant positive association was observed between circulating 
OPN levels and HCC risk. In analyses by tertiles of OPN concentrations, a strong, 
positive dose-response association was observed between HCC risk and OPN levels; 
multivariable OR (ORmultivariable) was 3.87 [95% CI: 1.27-11.78] and 13.76 [95% CI: 
4.21-44.98] for second (OPN: 49.1-58.6 ng/ml) and third (OPN: >58.6 ng/ml) tertiles vs. 
first (OPN: <49.1 ng/ml) tertile, respectively (p-trend<0.0001) (Table 2). Additionally, 
ORs for 10% increment in OPN level in crude and multivariable adjusted models were 
1.33 [95% CI: 1.19-1.49] and 1.30 [95% CI: 1.14-1.48], respectively (Table 2). The 
association between circulating OPN levels and HCC risk was stronger than the 
association between AFP levels and HCC risk; although circulating AFP level at 
baseline was also associated with higher HCC risk when analysed continuously or in 
tertiles, ORmultivariable for 10% increment in AFP level was 1.17 [95% CI: 1.09-1.25] and 
ORsmultivariable for second and third tertiles vs. first tertile were 1.97 [95% CI: 0.72-5.41] 
and 9.97 [95% CI: 3.70-26.86], respectively (p-trend<0.0001) (Table 2). Finally, cubic 
spline representation showed that the association between OPN levels and HCC 
increased linearly when OPN level was above 47.15 ng/ml (Supplementary Figure S2). 
In separate models, we evaluated potential interactions of the association 
between OPN levels and HCC risk by sex, age at recruitment, baseline and lifetime 
alcohol consumption and smoking status. We did not observe any statistically 
significant effect modifications (all P for interaction > 0.05). Additional adjustment for 
AFP, BARD score, AST/ALT ratio, liver function tests and HBV/HCV status did not 
alter the findings for OPN (Supplementary Table S2). The association between 
circulating OPN levels and HCC risk was stronger among men than women 
(ORmultivariable  per 10% increase: 1.44 [95% CI: 1.19-1.74] and 1.07 [95% CI: 0.87-1.32], 
respectively) (Supplementary Table S2). The association between circulating OPN 
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levels and HCC risk was also stronger for cases diagnosed during the first 2 years (n=21) 
or from 2 to 6 years (n=40) of follow-up (ORmultivariable: 2.51 [95% CI: 1.06-5.95] and 
1.45 [95% CI: 1.13-1.85], respectively) compared to cases diagnosed after 6 years or 
more (n=39) of follow-up (ORmultivariable: 1.05 [95% CI: 0.89-1.24]) (Supplementary 
Table S2). However, the associations did not differ significantly by sex or years of 
follow-up (all P-values for heterogeneity>0.10). Models stratified by viral hepatitis 
status showed that while circulating OPN levels were significantly associated with 
higher HCC risk in both HBV/HCV positive and negative subjects, the association was 
stronger in HBV/HCV positive subjects (ncases=27; ORmultivariable: 2.45 [95% CI: 1.24-
4.83]) than in negative subjects (ncases=70; 1.19 [95% CI: 1.05-1.34]) (Supplementary 
Table S2). Finally, the association between OPN levels and HCC risk did not change 
substantially after excluding participants with AFP levels ≥ 20 or ≥ 10 ng/ml and after 
exclusion of participants that self-reported type 2 diabetes at baseline (Supplementary 
Table S2). 
 
Diagnostic Performance of OPN for HCC Risk  
Receiver operating characteristics (ROC) curves were constructed to evaluate 
OPN performance as a marker for HCC risk in all participants and among cases 
diagnosed within two years of follow-up. ROC curves were also used to assess whether 
the addition of AFP or liver enzymes AST, GGT and ALP improved the model. The 
performance of OPN alone or in combination with AFP or liver enzymes, in 
discriminating HCC cases from controls are presented in Figure 1. When including all 
HCC cases (Figure 1A), the AUC for OPN (0.71 [95% CI: 0.64-0.77] was lower than 
for AFP (0.76 [95% CI: 0.70-0.82]) or for liver enzymes GGT, ALP and AST (0.84 [95% 
CI: 0.78-0.89]). AUC increased to 0.86 [95% CI: 0.81-0.91] when both liver enzymes 
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and OPN were included in the model and further addition of AFP did not improve the 
performance. To further validate the performance of OPN alone or in combination with 
AFP and liver enzymes, we performed a 5-fold cross-validation analysis. The average 
from 5 runs showed similar AUC averages on classifier calibration and classifier 
validation (Supplementary Table S3). At 90% specificity, sensitivity was 72% for the 
model with OPN and liver enzymes in detecting HCC. 
When OPN performance was evaluated specifically for HCC cases diagnosed 
during the first 2 years of follow-up (Figure 1B), the AUC for OPN (0.82 [95% CI: 
0.72-0.91]) was higher than for AFP (0.79 [95% CI: 0.67-0.92] or for liver enzymes 
(0.79 [95% CI: 0.66-0.92]), respectively). AUC increased to 0.88 [95% CI: 0.78-0.98] 
when OPN and AFP were combined in the model. Similarly, when OPN and liver 
enzymes were combined in the model, the AUC increased to 0.87 [95% CI: 0.78-0.96]. 
However, a combination of OPN, AFP and liver enzymes did not improve the 
performance (AUC=0.87 [95% CI: 0.77-0.96]). At 85% specificity, sensitivity was 85% 
for the model with OPN and AFP in detecting HCC within 2 years of HCC diagnosis.  
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Discussion 
In this study, we observed a statistically significant positive association between 
plasma OPN levels and risk of first incident HCC. The results were stronger among 
cases diagnosed during the first years of follow-up, and did not change substantially 
after excluding hepatitis positive participants, or after adjustment for biomarkers of liver 
function. Also, among cases diagnosed during the first two years of follow-up, OPN 
alone or in combination with AFP showed better diagnostic performance of HCC 
compared to AFP alone.  
Most HCC cases are diagnosed at a late stage when curative treatments are not 
applicable. A recent multi-regional retrospective study showed that survival from first 
HCC treatment varied significantly by region, with median overall survival of 60, 33, 
31, 24 and 23 months for Japan, North America, South Korea, Europe and China, 
respectively (P<0.0001), underscoring the need for earlier HCC diagnosis worldwide 
(23). Given the rising incidence of this cancer in developed countries, it is critically 
important to identify those at high risk for HCC and institute effective surveillance 
strategies for early diagnosis. HCC is a cancer well suited for screening given its 
occurrence in identifiable high risk populations such as patients with liver cirrhosis or 
chronic HBV infection status. While surveillance for HCC in patients with cirrhosis is 
recommended, the uptake of HCC surveillance by the medical community has been 
poor. Better assessment of an individual’s risk of HCC could help clinicians increase 
adherence to screening programs. Most prediction models for HCC have been 
developed in high risk groups such as patients with liver cirrhosis or chronic HBV or 
HCV infection (24-32) and most models included age and levels of transaminases. Only 
two studies on HCC risk prediction models have been performed on the general 
population and both of them were performed in large cohorts from Taiwan (33, 34).  
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In the first Taiwanese population cohort study, transaminase levels were shown 
to be predictive of HCC development within 10 years independently of known HCV or 
HBV infection status (33). In that cohort the average of follow-up for HCC incidence 
was 8.5 years. In the second Taiwanese population cohort study, family history of HCC 
and cumulative smoking improved a model based on transaminases alone (34). All these 
models, whether they were developed on high risk groups or in general populations, 
used only a combination of readily available parameters and liver function tests such as 
liver transaminase or albumin. Our study is the first to include a novel HCC biomarker. 
While we also found that liver function tests indicative of liver injury, could predict 
HCC development in the EPIC cohort independently of HCV or HBV infection status, 
we showed that a model based on liver function can be moderately improved by the 
addition of OPN. We have previously identified OPN as an early stage HCC biomarker 
in patients with liver cirrhosis or chronic hepatitis and showed that OPN is already 
elevated a year prior to diagnosis (8). We also reported that OPN and AFP are 
complementary for the detection of HCC. In the EPIC pre-diagnosis samples, addition 
of AFP did not further improve the OPN-based prediction model.  
Most remarkably, the performance and the composition of the OPN prediction 
model changed in relation to time to HCC diagnosis. Within two years of diagnosis, the 
combination of OPN and AFP best predicted HCC development and liver function tests 
did not improve the model, suggesting that measuring OPN and AFP could identify 
high risk groups independently of a cirrhosis diagnosis. In most studies, the clinical 
utility of HCC risk models has not been evaluated. At the population level, an ideal 
model is an easy-to-use model that should encourage at-risk people to be screened. 
Information provided by the OPN-AFP prediction model could allow the clinician to 
identify patients at high risk of developing HCC within two years and requiring HCC 
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surveillance with imaging modalities such as MRI or CT that are highly sensitive for the 
detection of small HCCs.  
OPN is a secreted non-collagenous, matrix glycoprotein, implicated in the 
progression of fibrosis and cancer and an influential factor in the tumor 
microenvironment (35,36). In the liver, OPN has been shown to modulate regeneration, 
inflammation and fibrosis and more recently, to induce dedifferentiation of hepatocytes 
(37,38). Our group has also shown that OPN is necessary for the survival of CD24+ 
liver progenitor cells (39). Both dedifferentiation of hepatocytes and accumulation of 
CD24+ cells have been proposed as early events in HCC tumor initiation (40,41). The 
effect of OPN on hepatocyte dedifferentiation and accumulation of liver progenitor cells 
is also in agreement with the observed negative correlation between OPN and albumin, 
a marker of mature hepatocytes.   
A strength of our study is its reliance on a prospective cohort design which 
allowed the estimation of OPN concentrations prior to cancer diagnosis, and the 
coverage of several European countries with variable prevalence patterns of exposures 
relevant to HCC risk. Other strengths of the study include the use of a uniform protocol 
and the centralized laboratory determinations of markers of HBV/HCV infections and 
liver function markers. The study has however several limitations. While the sample 
size can be considered adequate for a cohort study in Caucasians, among whom HCC is 
a relatively rare tumor, the study suffers from small sample size when focusing on 
subgroups. This is particularly the case for the analysis of OPN performance within 2 
years prior to HCC diagnosis. The comparative estimation of HCC risk by OPN 
between subgroups, such as men and women, may also not reach statistical significance 
due to the small sample size. Another limitation of this study is the lack of information 
on the presence of fibrosis, cirrhosis or other chronic liver diseases. Although we were 
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able to adjust for a number of important risk factors, liver function markers, and 
hepatitis infection status, the presence of possible residual confounding may not be 
ruled out.  
In conclusion, this study has shown that higher pre-diagnostic OPN levels in 
plasma is associated with higher risk of first incident HCC among Europeans. 
Assessment of the risk of HCC development is essential for formulating personalized 
surveillance or for prevention strategies. We identified simple models using OPN 
circulating levels, for the identification of patients at high risk of developing HCC and 
for use as a decision rule for clinical action. Because these models are independent of 
known risk factor for HCC, they could have utility in assessing individual annual risk of 
developing HCC in subjects previously thought to be at low or average risk because of 
unknown risk factors or undiagnosed cirrhosis. Large prospective studies, and studies in 
other populations, are needed to further optimize the model in relation to time of 
diagnosis and to evaluate its utility as a decision rule for clinical action. 
  
Cancer Research. 
on July 14, 2016. © 2016 American Association forcancerpreventionresearch.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 23, 2016; DOI: 10.1158/1940-6207.CAPR-15-0434 
24 
 
References 
1. Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, 
Forman D, Bray F. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 
11. Globocan [Internet]. 2013  [cited 1.0 September 17, 2015]; Available from: 
http://globocan.iarc.fr 
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer 
statistics. CA: a cancer journal for clinicians. 2011;61:69-90. 
3. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118-27. 
4. Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best 
Pract Res Clin Gastroenterol. 2014;28:753-70. 
5. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. 
Nature reviews Gastroenterology & hepatology. 2013;10:656-65. 
6. Singal AG, Conjeevaram HS, Volk ML, Fu S, Fontana RJ, Askari F, et al. 
Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer 
Epidemiol Biomarkers Prev. 2012;21:793-9. 
7. van Meer S, de Man RA, Siersema PD, van Erpecum KJ. Surveillance for 
hepatocellular carcinoma in chronic liver disease: evidence and controversies. World 
journal of gastroenterology : WJG. 2013;19:6744-56. 
8. Shang S, Plymoth A, Ge S, Feng Z, Rosen HR, Sangrajrang S, et al. 
Identification of osteopontin as a novel marker for early hepatocellular carcinoma. 
Hepatology. 2012;55:483-90. 
9. da Costa AN, Plymoth A, Santos-Silva D, Ortiz-Cuaran S, Camey S, Guilloreau 
P, et al. Osteopontin and latent-TGF beta binding-protein 2 as potential diagnostic 
markers for HBV-related hepatocellular carcinoma. International journal of cancer 
Journal international du cancer. 2015;136:172-81. 
Cancer Research. 
on July 14, 2016. © 2016 American Association forcancerpreventionresearch.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 23, 2016; DOI: 10.1158/1940-6207.CAPR-15-0434 
25 
 
10. Nabih MI, Aref WM, Fathy MM. Significance of plasma osteopontin in 
diagnosis of hepatitis C virus-related hepatocellular carcinoma. Arab journal of 
gastroenterology : the official publication of the Pan-Arab Association of 
Gastroenterology. 2014;15:103-7. 
11. Wan HG, Xu H, Gu YM, Wang H, Xu W, Zu MH. Comparison osteopontin vs 
AFP for the diagnosis of HCC: a meta-analysis. Clinics and research in hepatology and 
gastroenterology. 2014;38:706-14. 
12. Ge T, Shen Q, Wang N, Zhang Y, Ge Z, Chu W, et al. Diagnostic values of 
alpha-fetoprotein, dickkopf-1, and osteopontin for hepatocellular carcinoma. Medical 
oncology. 2015;32:59. 
13. Rittling SR, Chambers AF. Role of osteopontin in tumour progression. Br J 
Cancer. 2004;90:1877-81. 
14. Chakraborty G, Jain S, Behera R, Ahmed M, Sharma P, Kumar V, et al. The 
multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. 
Current molecular medicine. 2006;6:819-30. 
15. Weber GF, Lett GS, Haubein NC. Osteopontin is a marker for cancer 
aggressiveness and patient survival. Br J Cancer. 2010;103:861-9. 
16. Zhang CH, Xu GL, Jia WD, Ge YS, Li JS, Ma JL, et al. Prognostic significance 
of osteopontin in hepatocellular carcinoma: a meta-analysis. International journal of 
cancer Journal international du cancer. 2012;130:2685-92. 
17. Riboli E, Kaaks R. The EPIC Project: rationale and study design. European 
Prospective Investigation into Cancer and Nutrition. International journal of 
epidemiology. 1997;26 Suppl 1:S6-14. 
Cancer Research. 
on July 14, 2016. © 2016 American Association forcancerpreventionresearch.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 23, 2016; DOI: 10.1158/1940-6207.CAPR-15-0434 
26 
 
18. Riboli E, Hunt KJ, Slimani N, Ferrari P, Norat T, Fahey M, et al. European 
Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data 
collection. Public health nutrition. 2002;5:1113-24. 
19. Trichopoulos D, Bamia C, Lagiou P, Fedirko V, Trepo E, Jenab M, et al. 
Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested 
case-control study. J Natl Cancer Inst. 2011;103:1686-95. 
20. Fedirko V, Lukanova A, Bamia C, Trichopolou A, Trepo E, Nothlings U, et al. 
Glycemic index, glycemic load, dietary carbohydrate, and dietary fiber intake and risk 
of liver and biliary tract cancers in Western Europeans. Annals of oncology : official 
journal of the European Society for Medical Oncology / ESMO. 2013;24:543-53. 
21. Fedirko V, Duarte-Salles T, Bamia C, Trichopoulou A, Aleksandrova K, 
Trichopoulos D, et al. Prediagnostic circulating vitamin D levels and risk of 
hepatocellular carcinoma in European populations: a nested case-control study. 
Hepatology. 2014;60:1222-30. 
22. Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. 
Development and validation of a simple NAFLD clinical scoring system for identifying 
patients without advanced disease. Gut. 2008;57:1441-7. 
23. Park JW, Chen M, Colombo M, Roberts LR, Schwartz M, Chen PJ, et al. Global 
patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE 
Study. Liver Int. 2015;35:2155-66. 
24. Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, Yuen JC, et al. Independent 
risk factors and predictive score for the development of hepatocellular carcinoma in 
chronic hepatitis B. Journal of hepatology. 2009;50:80-8. 
Cancer Research. 
on July 14, 2016. © 2016 American Association forcancerpreventionresearch.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 23, 2016; DOI: 10.1158/1940-6207.CAPR-15-0434 
27 
 
25. Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, et al. 
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related 
advanced liver disease. Gastroenterology. 2009;136:138-48. 
26. Yang HI, Yuen MF, Chan HL, Han KH, Chen PJ, Kim DY, et al. Risk 
estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): 
development and validation of a predictive score. The lancet oncology. 2011;12:568-74. 
27. Michikawa T, Inoue M, Sawada N, Iwasaki M, Tanaka Y, Shimazu T, et al. 
Development of a prediction model for 10-year risk of hepatocellular carcinoma in 
middle-aged Japanese: the Japan Public Health Center-based Prospective Study Cohort 
II. Preventive medicine. 2012;55:137-43. 
28. Kurosaki M, Hiramatsu N, Sakamoto M, Suzuki Y, Iwasaki M, Tamori A, et al. 
Data mining model using simple and readily available factors could identify patients at 
high risk for hepatocellular carcinoma in chronic hepatitis C. Journal of hepatology. 
2012;56:602-8. 
29. Lee MH, Yang HI, Liu J, Batrla-Utermann R, Jen CL, Iloeje UH, et al. 
Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic 
hepatitis B patients: risk scores integrating host and virus profiles. Hepatology. 
2013;58:546-54. 
30. Lee MH, Lu SN, Yuan Y, Yang HI, Jen CL, You SL, et al. Development and 
validation of a clinical scoring system for predicting risk of HCC in asymptomatic 
individuals seropositive for anti-HCV antibodies. PLoS One. 2014;9:e94760. 
31. Flemming JA, Yang JD, Vittinghoff E, Kim WR, Terrault NA. Risk prediction 
of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model. 
Cancer. 2014;120:3485-93. 
Cancer Research. 
on July 14, 2016. © 2016 American Association forcancerpreventionresearch.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 23, 2016; DOI: 10.1158/1940-6207.CAPR-15-0434 
28 
 
32. El-Serag HB, Kanwal F, Davila JA, Kramer J, Richardson P. A new laboratory-
based algorithm to predict development of hepatocellular carcinoma in patients with 
hepatitis C and cirrhosis. Gastroenterology. 2014;146:1249-55 e1. 
33. Wen CP, Lin J, Yang YC, Tsai MK, Tsao CK, Etzel C, et al. Hepatocellular 
carcinoma risk prediction model for the general population: the predictive power of 
transaminases. J Natl Cancer Inst. 2012;104:1599-611. 
34. Hung YC, Lin CL, Liu CJ, Hung H, Lin SM, Lee SD, et al. Development of risk 
scoring system for stratifying population for hepatocellular carcinoma screening. 
Hepatology. 2015;61:1934-44. 
35. Kothari AN, Arffa ML, Chang V, Blackwell RH, Syn WK, Zhang J, et al. 
Osteopontin-A master regulator of epithelial-mesenchymal transition. J Clin Med. 2016; 
In press  
36.  Shevde LA, Samant RS. Role of osteopontin in the pathophysiology of cancer. 
Matrix Biology. 2014;37:131-41. 
37. Nagoshi S. Osteopontin: Versatile modulator of liver diseases. Hepatol Res. 
2014;44:22-30. 
38.  Yovchey MI, Locker J, Oertel M. Biliary fibrosis drives liver repopulation and 
phenotype transition of transplanted hepatocytes. J Hepatol. 2016; In press 
39.  Zhang J, Jiao J, Cermelli S, Muir K, Jung KH, Zou R, et al. miR-21 inhibition 
reduces liver fibrosis and prevents tumor development by inducing apoptosis of CD24+ 
progenitor cells. Cancer Res. 2015;75:1859-67. 
40.  Mu X, Espanol-Suner R, Mederacke I, Affò S, Manco R, Sempoux C, et al. 
Hepatocellular carcinoma originates from hepatocytes and not from the 
progenitor/biliary compartment. J Clin Invest. 2015;125:3891-903. 
Cancer Research. 
on July 14, 2016. © 2016 American Association forcancerpreventionresearch.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 23, 2016; DOI: 10.1158/1940-6207.CAPR-15-0434 
29 
 
41. Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. CD24(+) liver tumor-
initiating cells drive self-renewal and tumor initiation through STAT3-mediated 
NANOG regulation. Cell Stem Cell. 2011;9:50-63. 
  
Cancer Research. 
on July 14, 2016. © 2016 American Association forcancerpreventionresearch.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 23, 2016; DOI: 10.1158/1940-6207.CAPR-15-0434 
30 
 
Table 1. Characteristics of EPIC cohort subjects with incident HCC (Cases) and 
matched controls (Controls) selected for the nested case-control study. 
Baseline characteristics 
HCC  
cases  
(n=100) 
Matched 
controls (n=194) 
p-value 
Men, N (%) 70 (70.0) 136 (70.1) 
matching 
criteria 
Age at recruitment (y), mean (SD) 60.6 (6.6) 60.6 (6.7) 
matching 
criteria 
Follow-up from blood collection (y), mean (SD) 4.8 (2.9) -- -- 
Smoking status, N (%) 
  
<0.001 
 
Never smoker 25 (25.0) 79 (40.7)  
 
Former smoker  37 (37.0) 83 (42.8)  
 
Current smoker 36 (36.0) 31 (16.0)  
With diabetes, N (%)a 14 (14.0) 10 (5.2) 0.024 
Body Mass Index (kg/m2), mean (SD) 27.9 (5.3) 26.5 (3.6) 0.004 
Physical activity, N (%)b 
  
0.230 
 
Inactive 4 (4.0) 24 (12.4)  
 
Moderately inactive 31 (31.0) 58 (30.0)  
 
Moderately active 50 (50.0) 87 (44.9)  
 
Active 10 (10.0) 18 (9.3)  
Lifetime pattern of alcohol intake, N (%) 
  
<0.001 
 
Never drinkers 10 (10.0) 6 (3.1)  
 
Former drinkers 13 (13.0) 4 (2.1)  
 
Drinkers only at recruitment 17 (17.0) 43 (22.2)  
 
Lifetime drinkers 60 (30.0) 141 (72.7)  
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Alcohol intake at recruitment (g/d), mean (SD) 19.7 (28.1) 15.2 (18.6) 0.063 
Viral Hepatitis status, N (%)    
 Hepatitis B virus (HBV) positive 12 (12.0) 5 (2.6) 0.001 
 Hepatitis C virus (HCV) positive 18 (18.0) 4 (2.1) <0.001 
 HBV or HCV positive 27 (27.0) 8 (4.2) <0.001 
Baseline serum biomarkers, median (5th-95th 
percentile)  
 
 
 
α-fetoprotein (AFP), ng/ml 6.4 (2.5-744.6) 3.9 (1.9-9.0) 0.014 
C reactive protein (CRP), mg/l 2 (1-29.5) 1 (1-7) <0.001 
Liver function tests    
 Alanineaminotransferase (ALT), U/l 33 (10-139.5) 7 (9-45) <0.001 
 Aspartateaminotransferase (AST), U/l 45 (15-147) 19 (13-33) <0.001 
 Gamma-glutamyltransferase (GGT), U/l 87 (13-705) 23 (10-75) <0.001 
 Alkaline phosphatase (ALP), U/l 85 (44-177.5) 59 (38-100) <0.001 
 Albumin, g/l 39 (31-46.5) 42 (37-48) <0.001 
 Total bilirubin, μmol/l 10 (4-33) 8 (4-16) <0.001 
AST/ALT ratio 1.1 (0.6-2.5) 1.1 (0.6-1.9) 0.0214 
BARD score,N (%)   0.002 
 0-1 19 (19.0) 29 (15.0)  
 2 39 (39.0) 116 (59.8)  
 3-4 42 (42.0) 49 (25.3)  
Osteopontin (OPN), ng/ml 67.4 (29.1-167.3) 53.7 (27.1-93.6) <0.001 
SD, standard deviation. Missing values were not excluded from percentage calculations; 
therefore the sum of percent across subgroups may not add up to 100%. Categorical 
variables are presented as numbers and percentages; continuous variables are presented 
as mean and standard deviations. Case-control differences were assessed using 
Student’s paired t-test, Wilcoxon’s signed rank test or McNemar’s test where 
appropriate. 
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a Self-reported data. Number of cases and controls with missing data on diabetes status 
= 24. 
b Total physical activity categories were sex-specific. Number of cases and controls with 
missing data on physical activity = 12. 
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Table 2. Odds ratios and 95% confidence intervals for HCC by tertiles of circulating 
OPN and AFP levels in the EPIC nested case-control study. 
 
 
Tertiles 
Ptrend 
Continuously, 
per 10% 
increasea  
1 2 3 
OPN      
Tertile range, (ng/ml) <49.1 49.1-58.6 >58.6     
No of cases/controls 14/65 24/65 62/64 
 
  
Matching factors onlyb 1.00 3.09 [1.17-8.13] 12.26 [4.40-34.10] <0.0001 1.33 [1.19-1.49] 
Multivariablec 1.00 3.87 [1.27-11.78] 13.76 [4.21-44.98] <0.0001 1.30 [1.14-1.48] 
AFP      
Tertile range, (ng/ml) <3.3 3.3-4.6 >4.6   
No of cases/controls 9/67 15/63 76/64   
Matching factors onlyb 1.00 2.02 [0.78-5.28] 12.48 [4.87-32.02] <0.0001 1.18 [1.11-1.25] 
Multivariablec 1.00 1.97 [0.72-5.41] 9.97 [3.70-26.86] <0.0001 1.17 [1.09-1.25] 
a OPN and AFP levels correspond to a 10% increment after log transformation. 
b Odds ratios and 95% confidence intervals estimated by conditional logistic regression 
conditioned on the matching factors. 
c Additionally adjusted for body mass index (kg/m2, continuous), smoking status (never, 
former, current, unknown), baseline alcohol intake (g/d, continuous), and lifetime 
alcohol intake pattern (never drinkers, former drinkers, drinkers only at recruitment, 
lifetime drinkers, unknown). 
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Figure Legends 
 
Fig. 1. Discriminatory accuracy of the models for predicting the development of 
HCC. Receiver operating characteristics (ROC) curves for OPN, AFP and liver 
enzymes in the diagnosis of hepatocellular carcinoma in the EPIC nested case-control 
study in (A) all cases (HCC cases=100) and (B) in cases diagnosed during the first 2 
years of follow-up (HCC cases=21). The area under the curve (AUC) is shown with 95% 
CIs. 
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